283 related articles for article (PubMed ID: 23147542)
1. Incidence and risk factors of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients having undergone autologous stem cell transplantation.
Then C; Hörauf N; Otto S; Pautke C; von Tresckow E; Röhnisch T; Baumann P; Schmidmaier R; Bumeder I; Oduncu FS
Onkologie; 2012; 35(11):658-64. PubMed ID: 23147542
[TBL] [Abstract][Full Text] [Related]
2. Incidence of bisphosphonate-related osteonecrosis of the jaw in consideration of primary diseases and concomitant therapies.
Assaf AT; Smeets R; Riecke B; Weise E; Gröbe A; Blessmann M; Steiner T; Wikner J; Friedrich RE; Heiland M; Hoelzle F; Gerhards F
Anticancer Res; 2013 Sep; 33(9):3917-24. PubMed ID: 24023329
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of bisphosphonate-related osteonecrosis of the jaw after kidney transplantation.
Park W; Lee SH; Park KR; Rho SH; Chung WY; Kim HJ
J Craniofac Surg; 2012 Sep; 23(5):e510-4. PubMed ID: 22976726
[TBL] [Abstract][Full Text] [Related]
4. A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates.
Thumbigere-Math V; Tu L; Huckabay S; Dudek AZ; Lunos S; Basi DL; Hughes PJ; Leach JW; Swenson KK; Gopalakrishnan R
Am J Clin Oncol; 2012 Aug; 35(4):386-92. PubMed ID: 22561331
[TBL] [Abstract][Full Text] [Related]
5. Dental implications of bisphophonate-related osteonecrosis.
Saldanha S; Shenoy VK; Eachampati P; Uppal N
Gerodontology; 2012 Sep; 29(3):177-87. PubMed ID: 22486711
[TBL] [Abstract][Full Text] [Related]
6. Role of intravenous dosage regimens of bisphosphonates in relation to other aetiological factors in the development of osteonecrosis of the jaws in patients with myeloma.
Jarnbring F; Kashani A; Björk A; Hoffman T; Krawiec K; Ljungman P; Lund B
Br J Oral Maxillofac Surg; 2015 Dec; 53(10):1007-11. PubMed ID: 26530732
[TBL] [Abstract][Full Text] [Related]
7. A study of 225 patients on bisphosphonates presenting to the bisphosphonate clinic at King's College Hospital.
Taylor T; Bryant C; Popat S
Br Dent J; 2013 Apr; 214(7):E18. PubMed ID: 23579162
[TBL] [Abstract][Full Text] [Related]
8. Dental extraction as a risk factor for bisphosphonate related osteonecrosis of the jaw in cancer patients: an update.
Utreja A; Almas K; Javed F
Odontostomatol Trop; 2013 Jun; 36(142):38-46. PubMed ID: 24073539
[TBL] [Abstract][Full Text] [Related]
9. Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis.
Tennis P; Rothman KJ; Bohn RL; Tan H; Zavras A; Laskarides C; Calingaert B; Anthony MS
Pharmacoepidemiol Drug Saf; 2012 Aug; 21(8):810-7. PubMed ID: 22711458
[TBL] [Abstract][Full Text] [Related]
10. Intravenous bisphosphonate-related osteonecrosis of the jaw: long-term follow-up of 109 patients.
Watters AL; Hansen HJ; Williams T; Chou JF; Riedel E; Halpern J; Tunick S; Bohle G; Huryn JM; Estilo CL
Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Feb; 115(2):192-200. PubMed ID: 23036797
[TBL] [Abstract][Full Text] [Related]
11. Factors influencing surgical treatment of bisphosphonate-related osteonecrosis of the jaws.
Wutzl A; Pohl S; Sulzbacher I; Seemann R; Lauer G; Ewers R; Drach J; Klug C
Head Neck; 2012 Feb; 34(2):194-200. PubMed ID: 21400630
[TBL] [Abstract][Full Text] [Related]
12. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws.
Carlson ER; Basile JD
J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):85-95. PubMed ID: 19371819
[TBL] [Abstract][Full Text] [Related]
13. Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation.
Blimark C; Veskovski L; Westin J; Rödjer S; Brune M; Hjorth M; Holmberg E; Andersson PO; Mellqvist UH
Eur J Haematol; 2011 Aug; 87(2):117-22. PubMed ID: 21535157
[TBL] [Abstract][Full Text] [Related]
14. Metastatic cancer identified in osteonecrosis specimens of the jaws in patients receiving intravenous bisphosphonate medications.
Carlson ER; Fleisher KE; Ruggiero SL
J Oral Maxillofac Surg; 2013 Dec; 71(12):2077-86. PubMed ID: 23945512
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) therapy. A critical review.
Vescovi P; Nammour S
Minerva Stomatol; 2010 Apr; 59(4):181-203, 204-13. PubMed ID: 20360666
[TBL] [Abstract][Full Text] [Related]
16. [Clinical investigation of bisphosphonate-related osteonecrosis of the jaws].
Dehari H; Tomihara K; Ueda M; Shimanishi M; Ono M; Sasaki T; Igarashi T; Shiratori K; Abe M; Ogi K; Nakamori K; Miyazaki A; Nagai I; Hiratsuka H
Gan To Kagaku Ryoho; 2009 Dec; 36(13):2587-92. PubMed ID: 20009460
[TBL] [Abstract][Full Text] [Related]
17. Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies.
Assael LA
J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):35-43. PubMed ID: 19371813
[TBL] [Abstract][Full Text] [Related]
18. Early surgical laser-assisted management of bisphosphonate-related osteonecrosis of the jaws (BRONJ): a retrospective analysis of 101 treated sites with long-term follow-up.
Vescovi P; Manfredi M; Merigo E; Guidotti R; Meleti M; Pedrazzi G; Fornaini C; Bonanini M; Ferri T; Nammour S
Photomed Laser Surg; 2012 Jan; 30(1):5-13. PubMed ID: 22054203
[TBL] [Abstract][Full Text] [Related]
19. Teriparatide therapy for bisphosphonate-related osteonecrosis of the jaw: a case report and narrative review.
Thumbigere-Math V; Gopalakrishnan R; Michalowicz BS
Northwest Dent; 2013; 92(1):12-8. PubMed ID: 23516715
[TBL] [Abstract][Full Text] [Related]
20. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
